Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
ProBioGen, a CDMO of complex glycoproteins and corresponding technologies, has announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics.
read more
Tuesday, September 16, 2025
ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process development and good manufacturing practice (GMP) production facility for Advanced Therapy Medicinal Products (ATMPs) at ...
read more
Wednesday, August 17, 2022
ProBioGen closed a Master Service Agreement with NextPoint and initiated development and GMP manufacturing of their lead antibody candidate.
read more
ProBioGen has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, a privately held immunology company.
read more
Monday, February 14, 2022
ProBioGen has announced a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology. Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate the ...
read more
Tuesday, January 07, 2025
ProBioGen announced the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of...
read more
Thursday, January 16, 2020
ProBioGen has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
read more
ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. MiGenTra will enhance the ...
read more
ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.
read more
Based upon its collaborative work with three pharmaceutical companies, PRISYM ID has launched an update to its flagship software solution for clinical supplies labeling.
read more
PRISM BioLab, Co. has entered into a drug discovery collaboration with Elix, Inc. The partnership will accelerate research on small molecule inhibitors of protein-protein interaction (PPI) targets by combining PRISM BioLab's proprietary peptide ...
read more
Dr. Havranek-Kosicek, previously Director of Finance and Control for the DSM Pharma Chemicals business unit of DSM Pharmaceutical Products, the pharmaceutical contract manufacturing and technology organization of Royal DSM N.V. (NYSE, Euronext: DSM ...
read more
As part of its CareCentered Contracting program Prime Therapeutics recently entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance.
read more
Friday, December 01, 2017
Prime Therapeutics and Biogen have partnered on an outcomes-based contract for several MS drugs as part of Prime's CareCentered Contract program.
read more
Wednesday, March 02, 2016
WuXi Biologics Co. and Prima BioMed Ltd. have announced that through their strategic supply partnership, Prima's first-in-class immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi's state-of-the-art cGMP facility ...
read more